Cancers of the gastrointestinal (GI) tract greatly contribute to the global cancer burden and cancer-related death. Claudin-18.2(CLDN18.2), a transmembrane protein, is a major component of tight junctions and plays an important role in the maintenance of barrier function. Its characteristic widespread expression in tumour tissues and its exposed extracellular loops make it an ideal target for researchers to develop targeted strategies and immunotherapies for cancers of the GI tract. In the present review, we focus on the expression pattern of CLDN18.2 and its clinical significance in GI cancer. We also discuss the tumour-promoting and/or tumour-inhibiting functions of CLDN18.2, the mechanisms regulating its expression, and the current progress regarding the development of drugs targeting CLDN18.2 in clinical research.
We embarked on as tructuralo ptimization campaign aimed at the discoveryo fn ovel anti-angiogenesis agents with previously reported imidazole kinase inhibitors as al ead compound. A library of 29 compounds was synthesized.S everal title compounds exhibited selective inhibitory activities against vascular endothelial growth factor receptor 2( VEGFR-2) over epidermal growth factor receptor( EGFR) kinase;t hese compounds also displayed selective and potent antiproliferative activity against three cancerc ell lines. The newly synthesized compounds were evaluated for anti-angiogenesis activity by chick chorioallantoic membrane( CAM) assay.A mong them, 1-(2-(2-chloro-phenyl)benzo[d]oxazol-5-yl)-3-(4-(trifluoromethoxy)phenyl)urea (compound 5n)s howedt he most potent anti-angiogenesis capacity,e fficient cytotoxic activities (in vitro against humanu mbilical vein endothelial cells (HUVEC), H1975, A549, and HeLa cell lines, with respectiveI C 50 valueso f8 .46, 1.40, 7.61, and 0.28 mm), and an acceptable level of VEGFR-2 kinase inhibition (IC 50 = 0.25 mm). Molecular docking analysisr evealed 5n to be at ype II inhibitor of VEGFR-2 kinase. In general, these results indicatet hat these 6-arylurea-2-arylbenzoxazole/benzimidazole derivatives are promisingi nhibitors of VEGFR-2 kinase for potentiald evelopment into anti-angiogenesis drugs.
Streptococcus is widely found in nature and the human body, and most species are not pathogenic. In recent years, studies have found that Streptococcus is associated with gastric cancer. Streptococcus was found to be enriched in the oral cavity, stomach and intestine of gastric cancer patients and found to be increased in gastric cancer tissues, suggesting that Streptococcus may be the pathogenic bacteria underlying gastric cancer. This review discusses the discovery of Streptococcus, the relationship between Streptococcus and gastric cancer, and the possible carcinogenic mechanism of Streptococcus and summarizes the progress of the research on the role of Streptococcus in gastric cancer to provide new ideas for the early detection, diagnosis and treatment of gastric cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.